Isavuconazole use and TDM in real-world pediatric practice Article Swipe

View

Related Concepts

Therapeutic drug monitoring Medicine Extracorporeal membrane oxygenation Mucormycosis Intensive care medicine Aspergillosis Drug Internal medicine Surgery Pharmacology Immunology

Berta Fernández Ledesma , Natalia Mendoza‐Palomar , Susana Melendo , Aurora Fernández-Polo , Berta Renedo , Alba Pau Parra , Sònia Luque , Santiago Grau Cerrato , Jaume Vima Bofarull , Marı́a Gómez , Montserrat Pujol Jover , María Isabel Benítez‐Carabante , Cristina Díaz de Heredia , Pere Soler‐Palacín ·

YOU? · · 2023 · Open Access · · DOI: https://doi.org/10.1128/aac.00829-23 · OA: W4388655666

Isavuconazole (ISA) is approved for treating invasive aspergillosis and mucormycosis in adults, but its use in children remains off-label. We report on the use of ISA in real-world pediatric practice with 15 patients receiving ISA for treatment of invasive fungal infections. Therapeutic drug monitoring (TDM) was performed in all patients, with 52/111 (46.8%) C trough determinations out of range, thus supporting the need for TDM in children, especially those receiving extracorporeal membrane oxygenation (ECMO).